• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Entellus Medical, Inc. is a medical technology company focused on the design, development and commercialization of products for the treatment of chronic sinusitis. Its XprESS family of products is used by ear, nose and throat, physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses. Entellus Medical was founded by Thomas V. Ressemann and Peter Keith in April 2006 and is headquartered in Plymouth, MN.
| Market Cap | 611.377 Million | Shares Outstanding | 25.474 Million | Avg 30-day Volume | 138.163 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.9 |
| Price to Revenue | 5.4524 | Debt to Equity | 0.5233 | EBITDA | -34.585 Million |
| Price to Book Value | 3.7838 | Operating Margin | -45.8091 | Enterprise Value | 483.839 Million |
| Current Ratio | 1.916 | EPS Growth | 0.065 | Quick Ratio | 1.657 |
| 1 Yr BETA | 0.4707 | 52-week High/Low | 0.0 / | Profit Margin | -31.2347 |
| Operating Cash Flow Growth | -72.4104 | Free Cash Flow to Firm (FCFF) TTM | -144.416 Million | Free Cash Flow to Equity (FCFE) TTM | 118.902 Million |
| Altman Z-Score | 1.4215 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
26,012,704 | 2018-02-28 | 0 | |
|
No longer subject to file | 2018-02-28 | 0 | |
|
No longer subject to file | 2018-02-28 | 0 | |
|
No longer subject to file | 2018-02-28 | 0 | |
|
No longer subject to file | 2018-02-28 | 0 | |
|
No longer subject to file | 2018-02-28 | 0 | |
|
No longer subject to file | 2018-02-28 | 0 | |
|
No longer subject to file | 2018-02-28 | 0 | |
|
No longer subject to file | 2018-02-28 | 0 | |
|
MOEN BRENT CFO AND SECRETARY |
|
No longer subject to file | 2018-02-28 | 0 |
|
WHITE ROBERT S. PRESIDENT AND CEO |
|
No longer subject to file | 2018-02-28 | 0 |
|
No longer subject to file | 2018-02-28 | 0 | |
|
WILLIAMSON THOMAS P. VP, COMMERCIAL OPERATIONS |
|
No longer subject to file | 2018-02-28 | 0 |
|
GONZALES DONALD A. CHIEF MEDICAL OFFICER |
|
No longer subject to file | 2018-02-28 | 0 |
|
ROSENTHAL MICHAEL HARRY CHIEF OPERATING OFFICER |
|
No longer subject to file | 2018-02-28 | 0 |
|
MENSINK KEVIN L VICE PRESIDENT, MARKETING |
|
7,500 | 2017-10-20 | 0 |
|
PETERSON KAREN E VP, REGULATORY AND QUALITY |
|
32,734 | 2017-10-09 | 0 |
|
PETRICK TIMOTHY B VP, RESEARCH & DEVELOPMENT |
|
92,385 | 2017-10-04 | 0 |
|
PAIDOSH STEPHEN R VICE PRESIDENT, OPERATIONS |
|
7,500 | 2017-09-13 | 0 |
|
CHRISTIAN MARTHA J. VICE PRESIDENT, REIMBURSEMENT |
|
0 | 2017-03-04 | 0 |
|
BURNHAM JONELLE R VICE PRESIDENT & GEN'L COUNSEL |
|
20,000 | 2017-02-04 | 0 |
|
INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. |
|
2,956,456 | 2017-01-31 | 0 |
|
ESSEX WOODLANDS HEALTH VENTURES VIII, L.L.C. ESSEX WOODLANDS HEALTH VENTURES VIII, L.P. ESSEX WOODLANDS HEALTH VENTURES FUND VIII LP |
|
3,231,656 | 2017-01-31 | 0 |
|
KOGL JEFF L VP, BUS. DEV. & STRATEGY |
|
7,500 | 2017-01-04 | 0 |
|
BOIANO MARGARET A VP HEALTHCARE POLICY&REIMBURSE |
|
0 | 2016-10-13 | 0 |
|
SUREK JAMES D VICE PRESIDENT, SALES |
|
95,031 | 2016-09-08 | 0 |
|
GRIFFIN THOMAS E CHIEF FINANCIAL OFFICER |
|
0 | 2016-01-04 | 0 |
|
INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. SV LIFE SCIENCES FUND IV (GP), L.P. |
|
3,489,531 | 2015-02-03 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
